Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels

Slides:

Advertisements

Similar presentations

New Insights in the Understanding of Cholesterol Metabolism: The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Regulation of Low-Density.

Advertisements

1 CLINICAL CHEMISTRY-2 (MLT 302) LIVER FUNCTION AND THE BILIARY TRACT LECTURE ONE Dr. Essam H. Aljiffri.

Cholesterol and C.V.D.. Learning outcome Most cholesterol is synthesised by the liver from saturated fats in the diet. Cholesterol is a component of cell.

Kirk Mykytyn, Ph.D. Department of Pharmacology

13.9 Cholesterol.

Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial Z. Awan, N.G. Seidah, J.G.

HYPERLIPIDEMIA  Coronary heart disease (CHD) is the cause of about half of all deaths. The incidence of CHD is correlated with elevated levels of low-density.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Discovery of a New Role of Human Resistin in Hepatocyte.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

Date of download: 7/9/2016 From: Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review Ann.

Beyond the Laboratory by Julian P.J. Halcox, and John E. Deanfield Circulation Volume 109(21 suppl 1):II-42-II-48 June 1, 2004 Copyright © American Heart.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Cholesterol metabolism

Evolocumab Drugbank ID : DB09303.

LDL cholesterol in CKD—to treat or not to treat?

Cholesterol is a soft fatty substance that is produced in the body and also obtained from food substances such as dairy products, eggs (egg yolk is rich.

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

by Hiroyuki Morita, and Issei Komuro

Robert Roberts, MD, FRCPC, MACC Canadian Journal of Cardiology

The effects of apo E alleles on various lipoprotein parameters

Three-dimensional Mapping of the Initiation of Nonsustained Ventricular Tachycardia in the Human Heart by Mina K. Chung, Steven M. Pogwizd, Dave P. Miller,

Nat. Rev. Cardiol. doi: /nrcardio

Arterioscler Thromb Vasc Biol

by Salim Yusuf, and Sonia Anand

CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.

by Kiran Musunuru, and Sekar Kathiresan

Value-Based Hypothesis Testing for Cardiac Device Clinical Trials

Vascular Progenitor Cells in Diabetes Mellitus

by Edward E. Morrisey Circulation Research Volume 109(6):

Site Selection and Performance in Clinical Trials

Circ Cardiovasc Qual Outcomes

So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients

Behavior and Biology: The Basic Sciences for AHA Action

Dual regulation of the LDL receptor—Some clarity and new questions

Effect of Provider Volume on the Accuracy of Hospital Report Cards

Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary.

Potassium Channels and Proliferation of Vascular Smooth Muscle Cells

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Sripal Bangalore, MD,

Figure 2 Hepatic action of functional foods and supplements

What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs? Raul D. Santos Atherosclerosis.

HW 1-5: Steroids, Lipids and Cardiovascular Disease

A review of PCSK9 inhibition and its effects beyond LDL receptors

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Lipopheresis in the nephrotic syndrome

Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency Don P. Wilson, MD, FNLA, Mark Friedman,

My Approach to the Patient With Familial Hypercholesterolemia

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche, PhD,

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

II. assessment of dyslipidemias

Definition Copyright © 2013 Pearson Education, Inc.. All rights reserved.

APOC3, Coronary Disease, and Complexities of Mendelian Randomization

Carmelo V. Venero, MD, Paul D. Thompson, MD, Antonio B. Fernandez, MD

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

Chapter 27: Drugs for Lipid Disorders

Copyright © 2016 Elsevier Inc. All rights reserved.

Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate

Copyright © 2013 Elsevier Inc. All rights reserved.

Figure 1 Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown)

LDL cholesterol in CKD—to treat or not to treat?

PC194 Ectopic Expression of Proprotein Convertase Subtilisin Kexin Type 9 by Smooth Muscular Cells Contributes to Aortic Dissection Yasunori IIda, Hiroki.

High-Density Lipoprotein Cholesterol Function Improves after Successful Treatment of Psoriasis: A Step Forward in the Right Direction Nehal N. Mehta,

Volume 87, Issue 1, Pages (January 2015)

Schematic representation of dyslipidaemia of metabolic syndrome.

Mediterranean diets: are they practical in the Western world?

Insights in the Understanding of Cholesterol Metabolism:

Lars E. Laugsand et al. BTS 2016;j.jacbts

in diabetic patients with mixed dyslipidemia

Fig. 2. Effects of CB_36 and its analogs in HepG2 cells

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels by Arman Qamar, and Deepak L. Bhatt Circulation Research Volume 117(8):662-664 September 25, 2015 Copyright © American Heart Association, Inc. All rights reserved.

The schematic demonstrates the mechanism of low-density lipoprotein (LDL) cholesterol reduction by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, the sources of hepatic cholesterol, and the role of cholesterol as a precursor for the synthesis of various metabolites, including steroid hormones. The schematic demonstrates the mechanism of low-density lipoprotein (LDL) cholesterol reduction by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, the sources of hepatic cholesterol, and the role of cholesterol as a precursor for the synthesis of various metabolites, including steroid hormones. LDL-R indicates LDL receptor; and VLDL, very low-density lipoprotein. Arman Qamar, and Deepak L. Bhatt Circ Res. 2015;117:662-664 Copyright © American Heart Association, Inc. All rights reserved.